CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
- None.
- None.
BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that two abstracts have been accepted for presentation at the Society for Healthcare Epidemiology of America (SHEA) conference being held in Houston, Texas, April 16 – 19, 2024.
The first abstract being presented examines in vitro antimicrobial activity of taurolidine against a set of recent clinical isolates representative of bacteria recovered from the LOCK-IT 100 trial and those commonly associated with CRBSI. Based on these data, taurolidine demonstrated broad antimicrobial activity against all gram-positive bacteria, including non-tuberculosis Mycobacteria (NTM), gram-negative bacteria, and fungal isolates tested. In addition, the activity of taurolidine was unaffected by resistance to common antibiotics.
A second abstract being presented highlights a retrospective analysis that was conducted to characterize demographics, outcomes and economics associated with the development of hospital acquired bloodstream infections (HA-BSI) in patients receiving hemodialysis through a CVC while in an inpatient setting. During the study period, all-cause mortality for patients with HA-BSI was
The abstract details are included below.
SHEA Conference Abstracts
Title: In Vitro Antimicrobial Activity of Taurolidine against Isolates Commonly Associated with Catheter-Related Bloodstream Infections
Timing: Thursday, April 18, 12:00 – 1:30pm CDT
Title: Impacts of Hospital Acquired Bloodstream Infections in Patients Undergoing Hemodialysis Through a Central Venous Catheter
Timing: Friday, April 19, 12:00 – 1:30pm CDT
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix anticipates the commercial launch of DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024, pending a timely implementation of TDAPA. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
What abstracts were accepted for presentation at the SHEA conference by CorMedix Inc.?
What is the focus of the first abstract being presented by CorMedix Inc. at the SHEA conference?
What bacteria did taurolidine demonstrate broad antimicrobial activity against according to the abstract presented by CorMedix Inc.?
What were the outcomes highlighted in the second abstract presented by CorMedix Inc. at the SHEA conference?
What was the all-cause mortality rate for patients with HA-BSI according to the abstract presented by CorMedix Inc.?
